A5066872937- Innovative Microfluidic and Catalytic Techniques Innovation
- Cardiac electrophysiology and arrhythmias
- Biosimilars and Bioanalytical Methods
- Pharmacogenetics and Drug Metabolism
- Pharmaceutical Economics and Policy
- Antibiotics Pharmacokinetics and Efficacy
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Diet and metabolism studies
- Liver physiology and pathology
- Acute Lymphoblastic Leukemia research
- Cardiomyopathy and Myosin Studies
- Chemical Reactions and Isotopes
- Mitochondrial Function and Pathology
- Mycobacterium research and diagnosis
- Pharmaceutical studies and practices
- Ion channel regulation and function
- Viral Infectious Diseases and Gene Expression in Insects
- 3D Printing in Biomedical Research
- Chemistry and Chemical Engineering
Sanofi (France)
2014-2024
1. The quantitative prediction of the pharmacokinetic parameters a drug from data obtained using human in vitro systems remains significant challenge i.e. metabolic clearance humans and estimation relative contribution enzymes involved clearance. This has become particularly problematic for low turnover compounds.2. Having hepatocytes with stable cellular function over several days that adequately mimic complexity physiological environment would be major advance. Thus, we evaluated...
The human absorption, distribution, metabolism, and excretion (hADME) study is the cornerstone of clinical pharmacology package for small molecule drugs, providing comprehensive information on rates routes disposition elimination drug-related material in humans through use
The in vitro metabolism of dronedarone and its major metabolites has been studied human liver microsomes cryopreserved hepatocytes primary culture through the use specific or total cytochrome P450 (CYP) monoamine oxidase (MAO) inhibitors. identification main enzymes participating their was also elucidated by using rhCYP, rhMAO, flavin monooxygenases (rhFMO) UDP-glucuronosyltransferases (rhUGT) liquid chromatography/tandem mass spectrometry (LC/MS-MS) analysis. Dronedarone extensively...
The intent of this perspective is to share the recommendations International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on fit‐for‐purpose metabolite bioanalysis support drug development registration. This report summarizes considerations trigger, timing, rigor various assessments address unique challenges due metabolites, with respect efficacy safety, which may arise during from investigational new (IND) enabling studies, phase...
Dilated cardiomyopathy (DCM) is a disease of the myocardium defined by left ventricular enlargement and systolic dysfunction leading to heart failure.Danicamtiv, new targeted myosin activator designed for treatment DCM, was characterised in vitro vivo preclinical studies.Danicamtiv human hepatic clearance predicted be 0.5 mL/min/kg from metabolic stability studies hepatocytes. For human, plasma protein binding moderate with fraction unbound 0.16, whole blood-to-plasma partitioning ratio 0.8,...
Embedded within the field of drug metabolism and pharmacokinetics (DMPK), biotransformation is a discipline that studies origins, disposition, structural identity metabolites to provide comprehensive safety assessment, including assessment exposure coverage in toxicological species. Spanning discovery development, metabolite identification (metID) scientists employ various strategies tools address stage-specific questions aimed at guiding maturation early chemical matter into candidates....
Tolebrutinib is a covalent inhibitor of Bruton’s tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are thought to be major drivers inflammation multiple sclerosis. This excretion balance metabolism study evaluated the metabolite profile tolebrutinib healthy male volunteers. Six volunteers received 60-mg oral dose [14C]-tolebrutinib, profiling 14C-labeled metabolites was performed using combination liquid chromatography, mass spectrometry,...